Jane

Dr Clare Slaney, Peter MacCallum Cancer Centre, Circle of 10 Melbourne

Dear Friends,

“The biggest challenge is chasing the funding to support our research. If we can increase funding, I believe this research could be the next breakthrough for breast cancer patients.”

– Dr Clare Slaney, NBCF Postdoctoral Research Fellow

Please join us in supporting world leading researcher Dr Clare Slaney.

Dr Slaney’s research is set to change the paradigms around breast cancer therapy with a ground-breaking project into gene engineering that will greatly enhance immunotherapy  treatments.

Breast cancer therapy using dual-specific T cells

Dr Clare Slaney and her team have conducted innovative research in the field of cancer immunotherapy, focusing on a novel approach called CAR T Cell therapy. Her research will produce a brand new type of molecule, called Bispecific Engager of APCs and T cells (BEAT).

This will be produced using gene engineering and biochemical methods and tested with various cells to help determine the best combinations for blocking tumours. The best BEAT will then be used in combination with an injection of CAR T cells against breast cancer, to examine its anti-tumour effects and safety.

If successful, this new combination of CAR T cells and BEAT could significantly enhance the effectiveness of immunotherapy for breast cancer treatment.

The National Breast Cancer Foundation is a charitable not-for-profit organisation, 100% reliant on philanthropic income, focussed on funding research to achieve zero deaths from breast cancer by 2030.

Thank you,

Jane

NBCF is endorsed by the Australian Taxation Office as a Deductible Gift
Recipient (DGR). Pursuant to Item 1 of the table in Section 30–15 of the income
Tax Assessment Act 1997, the NBCF can receive charitable gifts from individuals
making personal donations, corporations, as well as ancillary funds established
under Item 2. All gifts to the NBCF of $2 or more are fully tax deductible.